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ABSTRACT
Background
Glutathione S-transferases (GSTs) are known to abolish or reduce the activities of intracellular
enzymes that help detoxify environmental carcinogens, such as those found in tobacco smoke.
It has been suggested that polymorphisms in the GST genes are risk factors for lung cancer, but
a large number of studies have reported apparently conflicting results.
Methods and Findings
Literature-based meta-analysis was supplemented by tabular data from investigators of all
relevant studies of five GST polymorphisms (GSTM1 null, GSTT1 null, I105V, and A114V
polymorphisms in the GSTP1 genes, and GSTM3 intron 6 polymorphism) available before
August, 2005, with investigation of potential sources of heterogeneity. Included in the present
meta-analysis were 130 studies, involving a total of 23,452 lung cancer cases and 30,397
controls. In a combined analysis, the relative risks for lung cancer of the GSTM1 null and GSTT1
null polymorphisms were 1.18 (95% confidence interval [CI]: 1.14–1.23) and 1.09 (95% CI: 1.02–
1.16), respectively, but in the larger studies they were only 1.04 (95% CI: 0.95–1.14) and 0.99
(95% CI: 0.86–1.11), respectively. In addition to size of study, ethnic background was a
significant source of heterogeneity among studies of the GSTM1 null genotype, with possibly
weaker associations in studies of individuals of European continental ancestry. Combined
analyses of studies of the 105V, 114V, and GSTM3*B variants showed no significant overall
associations with lung cancer, yielding per-allele relative risks of 1.04 (95% CI: 0.99–1.09), 1.15
(95% CI: 0.95–1.39), and 1.05 (95% CI: 0.89–1.23), respectively.
Conclusions
The risk of lung cancer is not strongly associated with the I105V and A114V polymorphisms
in the GSTP1 gene or with GSTM3 intron 6 polymorphism. Given the non-significant
associations in the larger studies, the relevance of the weakly positive overall associations
with the GSTM1 null and the GSTT1 null polymorphisms is uncertain. As lung cancer has
important environmental causes, understanding any genetic contribution to it in general
populations will require the conduct of particularly large and comprehensive studies.
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Glutathione S-transferases (GSTs, Enzyme Commission
2.5.1.18) are a large family of cytosolic enzymes that catalyze
the detoxiﬁcation of reactive electrophilic compounds,
including many environmental carcinogens (e.g., benzo[a]-
pyrene and other polycyclic aromatic hydrocarbons) [1,2].
Inter-individual variability in GST enzyme activity is believed
to confer differences in susceptibility to cancers with major
environmental determinants such as lung cancer [3,4,5]. Some
genetic variants in the glutathione S-transferase genes, such
as the GSTM1 null polymorphism, are known to abolish
enzyme activities (Table 1). Because individuals with the
GSTM1 null genotype have been reported to have higher
levels of polycyclic aromatic hydrocarbon-dGMP adducts
(which can induce genetic mutations) in lung tissue than
those with the GSTM1 genotype [4], such genetic variants
have been extensively studied as candidates for lung cancer
susceptibility, but studies have yielded apparently conﬂicting
results [6–142]. This may be due, in part, to involvement of
only a few hundred cases and a few hundred controls in most
studies, too few to assess reliably any moderate genetic effects
in lung cancer. The interpretation of these studies has been
further complicated by studies involving: (i) different GST
polymorphisms, (ii) populations with different background
smoking patterns and with different ethnic compositions
(e.g., European and African populations have substantially
different frequencies of certain GST genetic variants), and
(iii) different control groups (e.g., population versus hospital
based).
Five common variants in four GST genes (GSTM1, GSTT1,
GSTP1, and GSTM3, described in Table 1) have been studied
extensively in relation to lung cancer, with each associated
with completely lost or reduced activities of certain xeno-
biotic metabolizing enzymes: (i) the GSTM1*0 (GSTM1 null),
(ii) the GSTT1*0 (GSTT1 null) alleles represent deletions of
the GSTM1 and GSTT1 genes, respectively, with each
conferring a total loss of activity in their corresponding
enzymes [5], (iii) the A to G transition in GSTP1 that gives rise
to the Ile105Val polymorphism (also known as I105V), (iv) the
C to T exchange at position 341 in the same gene, which
results in the Ala114Val polymorphism (also known as
A114V) (both of these GSTP1 polymorphisms confer moder-
ately reduced enzyme activity) [143], and (v) the GSTM3
intron 6 polymorphism, a 3-base pair deletion in intron 6,
which is in linkage disequilibrium with the GSTM1 genotype
and contains a recognition motif for the YY1 transcription
factor, which has been postulated to regulate gene expression
[144–146].
The present report provides a meta-analysis of published
genetic association studies, supplemented by tabular data
received from study investigators of these ﬁve GST variants
and risk of lung cancer. It includes an updated meta-analysis
of 119 association studies of the GSTM1 null polymorphism
and lung cancer (involving a total of 19,729 cancer cases and
25,931 controls, about three times as many participants as in
previous such reviews [147–149]), as well as completely new
syntheses of four other GST polymorphisms (i.e., the GSTT1
null polymorphism, I105V, and A114V polymorphisms in the
GSTP1 gene, and the GSTM3 intron 6 polymorphism). Hence,
in aggregate, the present meta-analysis involves a total of
23,452 cancer cases and 30,397 controls in 130 studies (with
the cases and controls in each study counted only once).
Methods
Data Searching
Genetic association studies published before August, 2005,
investigating at least one of the ﬁve polymorphisms in the
GST genes described above and lung cancer risk were sought
by computer-based searches, scanning of the reference lists
for all relevant studies and review articles (including meta-
analyses), hand searching of relevant journals, and corre-
spondence with authors of included studies. Computer
searches of PubMed, Web of Science, EMBASE, and CNKI
(http://www.cnki.net) used keywords relating to the relevant
genes (e.g., ‘‘GSTT1,’’ ‘‘GSTP1,’’ ‘‘GSTM3,’’ and ‘‘glutathione S-
transferase’’) in combination with words related to lung
cancer or lung-neoplasms without language restriction. All
relevant studies identiﬁed were included apart from one
study in which genotype frequencies were unavailable [120].
Twenty-two reports involved overlapping or duplicated data
with studies already included in the present review [121–142].
Table 1. Description of Glutathione S-Transferase Polymorphisms
Gene GSTM1 GSTM3 GSTP1 GSTT1
Chromosome location of gene 1p13.3 1p13.3 11q13.3 22q11.23
Length of gene 5.92 kb 4.53 kb 2.84 kb 8.09 kb
Number of exons 8 9 7 5
Position of polymorphism Deletion 3 bp-deletion in intron 6 A313G
(Ile105Val)
C341T
(Ala114Val)
Deletion
Enzyme activity Null [5] Uncertain [144,146] Reduced by ;30% [143] Null [5]
Main sites of tissue expression Liver, kidney, and adrenal Lung, testis, and brain Lung Liver and kidney
Main substrates Polycyclic aromatic
hydrocarbons, aflatoxins
Polycyclic aromatic
hydrocarbons, aflatoxins
N-acetylbenzoquinone imine,
4-nitroquinoline-1-oxide,
polycyclic aromatic hydrocarbons
Hydroxyalkylarenes, butadiene,
mono- and dihaloalkanes
Approximate frequencies of polymorphisms
in individuals of European continental
ancestry / Asians/ African Americans
50% / 51% / 30% 3% / ? / ? 10% / 2% / 14% 1% / ? / ? 24% / 51% / 25%
GSTM1, glutathione S-transferase M1; GSTM3, glutathione S-transferase M3; GSTP1, glutathione S-transferase P1; GSTT1, glutathione S-transferase T1; kb, kilobase; bp, base pair; ?, no data was available.
DOI: 10.1371/journal.pmed.0030091.t001
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The following information was abstracted from each study
according to a ﬁxed protocol: study design, geographical
location, ethnic group of participants, deﬁnition and
numbers of cases and controls, DNA extraction and genotyp-
ing methods, frequency of genotypes, mean age of lung
cancer cases, and proportion of lung cancer cases who were
male (Table S1). Previously un-reported data were included
from four of these studies following correspondence that
sought genotype frequencies on polymorphisms described in
this review that were not reported in the original publica-
tions. In the few instances in which genotype frequencies
provided by the investigators in tabular data differed slightly
from published ﬁgures, the tabular data were used. Studies
with different ethnic groups, and different source of controls
were considered as individual studies for our analyses
[6,9,10,17,23,27,41,55].
Statistical Methods
The per-allele odds ratio (‘‘relative risk’’) of the rare allele
(105V, 114V, GSTM3*B) was compared between cases and
controls by assigning scores of 0, 1, and 2 to common
homozygote, heterozygote, and rare homozygote, respec-
tively, and calculating odds ratios per unit score by logistic
regression; this is analogous to modeling a co-dominant
model of inheritance. Subsidiary analyses involved dominant
and recessive genetic models, where possible. For GSTM1 and
GSTT1 status with only two possible genotypes, the odds ratio
was compared between cases and controls by the Mantel-
Haenszel method. To make some allowance for multiple
comparisons, 99% conﬁdence intervals (CI) were used for
individual studies, and 95% CI were reserved for the
combined estimates. Random-effects and ﬁxed-effect sum-
mary measures were calculated as inverse-variance weighted
average of the log odds ratios. Heterogeneity was assessed
using the I
2 statistic, which describes the proportion of
variation in the log odds ratios that is attributable to genuine
differences across studies rather than to random error [150],
and by the v
2 test [151]. The among-study variance (s
2) was
used to quantify the degree of heterogeneity among studies
[152]. Percentage of s
2 explained is used to describe the
extent to which study-level characteristics (e.g., sample size,
sources of controls) explain heterogeneity, whereas the v
2 test
for interaction compares meta-analyses performed within
types of participants (e.g., cancer type, smoking status).
Subsidiary analyses involved subgroup analyses or random-
effects meta-regression. Publication bias was assessed using
funnel plots (so-called because, in the absence of publication
bias, such plots resemble symmetrical inverted funnels),
Begg’s test [153] and the Trim and Fill method [154], which
Figure 1. Meta-Analyses of Studies of Lung Cancer and Five GST Gene Polymorphisms (GSTM1 null, GSTT1 null, and GSTP1 I105V, GSTP1 A114V, and
GSTM3 intron 6) Grouped by Various Characteristics
DOI: 10.1371/journal.pmed.0030091.g001
PLoS Medicine | www.plosmedicine.org April 2006 | Volume 3 | Issue 4 | e91 0526
Lung Cancer and Meta-Analysisestimates the number and outcomes of potentially missing
studies due to publication bias. Study size (   500 cases, 200–
499 cases, and , 200 cases), source of controls (e.g.,
population versus hospital based), ethnicity (individuals of
European continental ancestry, East Asian, and other), and
cancer type (squamous, adenocarcinoma, small cell carcino-
ma, and other) were pre-speciﬁed as characteristics for
assessment of heterogeneity; other potentially relevant sub-
group analyses (such as age, sex, and smoking status) could
not reliably be investigated because individual participant
data were not available in this meta-analysis. Statistical
analyses were done using Stata (version 8.0) statistical
software (Stata Corporation, College Station, Texas, United
States). Because data on the joint occurrence of genetic
variants (such as the I105V and A114V polymorphisms) have
generally not been reported in published studies, analyses of
such haplotypes (i.e., combination of alleles at multiple
positions along a genomic segment of a single chromosome)
cannot be provided in this review. In the ﬁgures, areas of
squares of individual studies (or sets of studies) are inversely
proportional to the variances of the log odds ratios, and the
horizontal lines represent CIs. Studies in the ﬁgures are listed
in descending order of statistical weight.
Results
A total of 130 relevant genetic association studies (126
published and four unpublished) were identiﬁed, with 48
studies genotyping more than one variant (Table S1). For the
GSTM1 null polymorphism, 119 studies involved a total of
19,729 cases and 25,931 controls (weighted mean age of cases
63 years; 55% male). For the GSTT1 null polymorphism, 44
studies involved a total of 9,636 cases and 12,322 controls
(weighted mean age of cases 61 years; 59% male). For the
GSTP1 I105V polymorphism, 25 studies involved a total of
6,221 cases and 7,602 controls (weighted mean age of cases 64
years; 68% male) and for the A114V polymorphism of the
Figure 2. Meta-Analysis of Studies of GSTM1 Polymorphism and Lung Cancer
The horizontal axis is plotted on a log doubling scale.
DOI: 10.1371/journal.pmed.0030091.g002
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1,295 controls (weighted mean age of cases 61 years; 52%
male) [29,77,92,95]. For GSTM3 intron 6 polymorphism, ﬁve
studies involved a total of 1,238 cases and 1,179 controls
(weighted mean age of cases 62 years; 85% male)
[37,70,73,78,88].
Studies were conducted in a wide range of geographical
settings, with 48% of lung cancer cases being individuals of
European continental ancestry, 37% East Asian, and 15% of
other ethnic origins (including African American, Turkish,
and Mexican American) [8,17,22,41,64,67]. Of the 130 studies,
124 were retrospective case-control studies and six were
prospective in design (cohort or nested case-control)
[32,56,61,65,78,95]. Of the 124 retrospective studies, 80
involved controls drawn at random from approximately
general populations (e.g., population registers), 25 involved
controls from health-check visits or outpatient clinics, and 19
involved controls drawn from groups of patients free of
cancer. Of the 124 retrospective studies, 20 matched controls
to cases by age, and a further 26 matched controls to cases by
age and at least one other risk factor. All but one study [99]
used polymerase chain reaction/restriction fragment length
polymorphism with various restriction enzymes to perform
genotyping (the remaining study used oligonucleotide
probes).
There was evidence of a moderate degree of heterogeneity
among the 119 studies of the GSTM1 null genotype (I
2¼44%,
95% CI: 30% to 55%, p , 0.0001). Study characteristics such
as sample size (explaining 18% of s
2, p , 0.0001), and
ethnicity (44% of s
2, p , 0.0001) explained much of the
heterogeneity, whereas source of controls (0% of s
2, p¼0.82)
and cancer type (v
2
3 ¼ 1.49, p ¼ 0.69) explained a relatively
small fraction. Overall, the relative risk for lung cancer risk of
the GSTM1 null genotype was 1.22 (95% CI: 1.16–1.30) using a
random-effects model and 1.18 (95% CI: 1.14–1.23; Figures 1
and 2) using a ﬁxed-effect model, but a funnel plot of these
119 studies suggested a possibility of the preferential
publication of strikingly positive ﬁndings in smaller studies
(Begg’s test, p , 0.0001; Figure S1). Analysis restricted to the
ﬁve studies with at least 500 cases (total of 3,436 cases and
3,897 controls), which should be less prone to selective
publication than are the smaller studies, yielded a relative risk
of 1.04 (95% CI: 0.95–1.14), which is not statistically
signiﬁcant. Further evidence of selective publication derives
from the results of the Trim and Fill approach, which
suggested that 28 missing studies are required to make the
funnel plot symmetrical (Figure S2).
Figure 3. Meta-Analysis of Studies of GSTT1 Polymorphism and Lung Cancer
The horizontal axis is plotted on a log doubling scale.
DOI: 10.1371/journal.pmed.0030091.g003
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Lung Cancer and Meta-AnalysisThere was a moderately high degree of heterogeneity
among the 44 studies of the GSTT1 null genotype (I
2 ¼ 57%,
95% CI: 40% to 70%, p , 0.0001). Study characteristics such
as sample size (17% of s
2 explained, p ¼ 0.01) and ethnicity
(31% of s
2, p¼0.02) explained some of the heterogeneity, but
source of controls (0% of s
2, p ¼ 0.02) and cancer type (v
2
3 ¼
5.55, p¼0.14) did not explain much of it. Overall, the relative
risk for lung cancer of the GSTT1 null genotype was 1.13
(95% CI: 1.02–1.26) using a random-effects model and 1.09
(95% CI: 1.02–1.16; Figures 1 and 3) using a ﬁxed-effect
model. A funnel plot did not indicate the presence of
publication bias in these studies (Begg’s test p ¼ 0.14; plot
available on request), and an analysis of the four studies with
at least 500 cases (total of 2,767 cases and 3,110 controls)
yielded a relative risk of 0.99 (95% CI: 0.86–1.11).
There was no signiﬁcant heterogeneity among the 25
studies of the 105V variant in the GSTP1 gene and lung
cancer (I
2 ¼ 0% 95% CI: 0% to 44%, p ¼ 0.66). Overall, the
per-allele relative risk for lung cancer of the 105V variant was
1.04 (95% CI: 0.99–1.09; Figures 1 and 4), with corresponding
results under dominant and recessive genetic models of 1.02
(95% CI: 0.95–1.09) and 1.13 (95% CI: 1.01–1.27), respectively.
There was no signiﬁcant heterogeneity among the four
studies of the 114V variant of the same gene (I
2 ¼ 0%, 95%
CI: 0% to 85%, p ¼ 0.39). The overall per-allele risk of the
114V variant for lung cancer was 1.15 (95% CI: 0.95–1.39),
with corresponding results under dominant and recessive
genetic models of 1.17 (95% CI: 0.95–1.45) and 1.27 (95% CI:
0.48–3.33; Figures 1 and 5), respectively. There was no
signiﬁcant heterogeneity among the ﬁve studies of the
GSTM3*B variant (I
2 ¼ 0%, 95% CI: 0% to 79%, p ¼ 0.95).
The overall per-allele risk of the GSTM3*B variant for lung
cancer was 1.05 (95% CI: 0.89–1.23; Figures 1 and 6), with
corresponding results under dominant and recessive genetic
models of 1.11 (95% CI: 0.92–1.34) and 0.91 (95% CI: 0.52–
1.57), respectively.
Discussion
The present meta-analysis of 130 genetic association
studies involves more than 23,000 cases and 30,000 controls
and provides the most comprehensive assessment so far of the
relevance to lung cancer of ﬁve GST gene polymorphisms.
This review indicates that the risk of lung cancer is not
strongly associated with the I105V and A114V polymorphisms
in the GSTP1 gene or with the GSTM3 intron 6 poly-
morphism. The relevance of the weakly positive overall
associations observed of the GSTM1 null and of the GSTT1
null genotypes with the risk of lung cancer is uncertain,
particularly given the non-signiﬁcant relative risks observed
for each variant in the larger studies (which should be less
prone to selective reporting than are the smaller studies). At
least for the studies of the GSTM1 null variant, there is a
possibility that the magnitude of the association varies
signiﬁcantly by characteristics such as ethnic background.
The potential limitations of the present report merit
consideration. Although the available data on three of the
polymorphisms (i.e., GSTM1 null, GSTT1 null, and GSTP1
105V) comprise at least 6,000 cases and at least 7,000 controls
for each of these variants, the present data on the GSTP1
Figure 4. Meta-Analysis of Studies of GSTP1 I105V Polymorphism and Lung Cancer
The horizontal axis is plotted on a log doubling scale.
DOI: 10.1371/journal.pmed.0030091.g004
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1,000 cases and about 1,000 controls for each) are much
sparser—too few to enable reliable assessments of any per-
allele relative risks of about 10% to 20%. Even for the more
extensively studied variants, moreover, the present data are
insufﬁcient to enable reliable assessment of the impact of the
genotypes in potentially relevant subgroups, such as those
deﬁned by ethnic background or by cancer histology. Lack of
individual data in the present review prevents more detailed
analyses, such as any joint effects of gene-gene or gene-
environment factors. Funnel plots suggest publication bias in
studies of only one of the ﬁve variants considered (i.e., the
GSTM1 null genotype), but it is difﬁcult to exclude this bias in
studies of the four other variants despite our attempts to
identify un-reported data by correspondence with investi-
gators and exploration of data for the possible effects of
selective publication.
The pathways of carcinogen metabolism are complex,
mediated by the activities of multiple genes (such as GSTM1,
and CYP1A1 [3,155]). The effect of any single gene might have
more limited impact on lung cancer than has so far been
anticipated. The failure to demonstrate important associa-
tions between each of the ﬁve GST polymorphisms and lung
cancer does not necessarily exclude the possibility that other
variants (or combinations of alleles at multiple positions) in
the same genes could be materially relevant to lung cancer. A
more comprehensive empirical approach, in which all
common variants are identiﬁed by resequencing followed
by the genotyping of a tagging set of variants, may prove
productive [156,157]. The examples in this review, therefore,
illustrate the need for much larger and more comprehensive
studies than have been customary in order to evaluate
reliably any moderate genetic effects that might be realisti-
cally expected in a complex disease such as lung cancer,
which has known major environmental determinants [158].
Supporting Information
Figure S1. Funnel Plot of Studies of GSTM1 Null Polymorphism and
Lung Cancer Showing a Possible Excess of Smaller Studies with
Strikingly Positive Findings beyond the 95% CI; Begg’s Test, p ,
0.0001
Found at DOI: 10.1371/journal.pmed.0030091.sg001 (52 KB PPT).
Figure S2. Trimmed and Filled Funnel Plot of GSTM1 Null
Polymorphism and Lung Cancer
The hollow diamonds are the actual studies included in the meta-
analysis, the squares are the Trimmed and Filled studies required to
achieve symmetry.
Found at DOI: 10.1371/journal.pmed.0030091.sg002 (56 KB PPT).
Table S1. Characteristics of Genetic Association Studies of Five GST
Polymorphisms in the Present Meta-Analyses
Found at DOI: 10.1371/journal.pmed.0030091.st001 (670 KB DOC).
Accession Numbers
The UniGene (http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?db¼unigene) accession numbers used in this paper are GSTM1
(Hs.301961), GSTM3 (Hs.2006), GSTP1 (Hs.523836), and GSTT1
(Hs.77490).
The GeneCard (http://www.genecards.org) protein coding ID
numbers are GSTM1 (GC01P109942), GSTM3 (GC019988), GSTP1
(GC11P067107), and GSTT1 (GC22M022700).
Figure 5. Meta-Analysis of Studies of GSTP1 A114V and GSTM3 Intron 6 Polymorphisms and Lung Cancer
The horizontal axis is plotted on a log doubling scale.
DOI: 10.1371/journal.pmed.0030091.g005
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Patient Summary
Background. Genes and the environment determine a person’s risk of
cancer. For some cancers, strong environmental risk factors have been
identified. One such example is lung cancer, where the large majority of
cases are caused by smoking. However, some people who never smoke
get lung cancer, and some heavy smokers do not. To help understand
such cases, scientists have studied a group of genes called glutathione S-
transferase genes. These genes contain the genetic information to make
a group of proteins, the glutathione s-transferases, which detoxify
environmental poisons such as those contained in cigarette smoke.
Different people have slightly different versions of these genes. Some of
these gene variants are thought to result in less active or even
completely inactive proteins. Scientists have wondered whether these
different gene variants influence the lung cancer risk in smokers and
non-smokers. To find out, they have done a lot of studies, some small,
some large, to test whether there are associations between particular
glutathione s-transferase gene variants and the risk of lung cancer.
Why Was This Study Done? Such association studies compare a group
of people with lung cancer and a very similar group without lung cancer.
Researchers determine the genetic make-up of both groups and ask
whether a particular gene variant is more common among either the
cancer patients (the ‘‘cases’’) or the people without cancer (the
‘‘controls’’). A variant that is more common among the cases might
convey a risk, and one that is more common among the controls might
convey some level of protection. The larger the studies are, and the more
similar the cases and controls are, the better the chance to detect a
‘‘real’’ association. However, association studies are notoriously difficult
to interpret, and most scientists agree that several independent studies
are necessary before one can be reasonably sure that a particular gene
variant conveys a risk or a protection. A rigorous way to summarize and
integrate the results from several individual association studies is to do
what is called a meta-analysis.
What Did the Researchers Do and What Did They Find? These
researchers did such a meta-analysis of 130 studies. Together, the studies
tested possible associations between five relatively common variants in
four glutathione s-transferase genes and the occurrence of lung cancer.
All of the variants tested resulted in either less active or inactive versions
of the proteins. Some of the individual studies had found associations
between one or several of the variants and lung cancer (suggesting that
they conveyed a risk), others had not. Altogether, the studies included
data from over 23,000 lung cancer patients and 30,000 control
individuals without lung cancer. After summarizing all of the results, it
became clear that none of the five variants, not even the ones that
resulted in inactive proteins, conveyed a clearly strong risk for lung
cancer.
What Does This Mean? A rigorous assessment of the results to date
suggests that none of the five variants conveys a clearly strong risk for
lung cancer in the general population. The gene variants included were
some of the obvious ones to study, but there might be others that have
a strong influence on an individual’s risk to get lung cancer. It is also
possible that some of these gene variants convey a stronger risk in some
subgroups, for example, in particular ethnic groups that share a common
genetic background. Additional studies that look specifically at the risk in
particular subgroups would be needed to find out whether this is indeed
the case. And much larger studies would be needed to determine
reliably whether there are genes that convey a small or moderate risk for
(or protection against) lung cancer.
Where Can I Find More Information Online? The following pages
provide information on lung cancer and cancer genetics.
Pages from the US National Cancer Institute:
http://www.cancer.gov/cancertopics/types/lung
http://www.cancer.gov/cancertopics/prevention-genetics-causes/
genetics
MedlinePlus pages:
http://www.nlm.nih.gov/medlineplus/lungcancer.html
Cancer Research UK pages:
http://www.cancerhelp.org.uk/help/default.asp?page=2787
CancerIndex:
http://www.cancerindex.org/clinks2l.htm
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